Navigation Links
Studies uncover high and often overlooked costs associated with epilepsy
Date:4/30/2009

[Seattle] (April 29, 2009) Employees with epilepsy cost healthcare insurers and employers significantly more than those without the condition, according to findings from two studies presented here today at the American Academy of Neurology (AAN) Annual Meeting.

"These findings suggest that the true cost of epilepsy to third-party payors may often be underestimated when looking only at costs directly related to epilepsy," said Susan Caleo, Director of Health Economics and Neurology at Johnson & Johnson Pharmaceutical Services, Inc. (JJPSI). JJPSI sponsored the study in collaboration with Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

"In particular, the studies suggest that perhaps most overlooked among those with epilepsy are the costs associated with comorbidities, particularly mental health disorders," Caleo noted. "These findings underscore the need for physicians to treat the whole patient, beyond seizure control."

The first study was a 12-month retrospective analysis of the total cost of epilepsy to third-party payors, including insurers and employers. The study found that compared to those without the condition, people with epilepsy reported higher rates of mental disorders, substance abuse and other neurological and physical disorders.

Findings also noted that in people with epilepsy, the costs to third-party payors of these comorbidities, coupled with the condition itself, can be significant. The study compared the direct cost for the insurers among people with and without epilepsy, and found that on average, direct annual costs for third-party payors, such as medical and pharmaceutical costs, were nearly three times higher in people with epilepsy than those without the condition.

The second study analyzed indirect third-party payor epilepsy costs, such as disability and medically-related absenteeism. These expenses were more than three times higher in employees with
'/>"/>

Contact: Krystal Loewe
kloewe@golinharris.com
312-729-4453
Golin/Harris International
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Are we cherry picking participants for studies of antidepressants?
2. Wound Management Technologies, Inc. Announces the Presentation of Evidence Based Clinical Studies at the Symposium on Advanced Wound Care Conference in Dallas
3. Pharos Innovations and Clients to Showcase Three Client Case Studies at Upcoming ATA Conference
4. Gene Studies Reveal Cancers Secrets
5. NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
6. Mersanas Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
7. PRA SPEAKING EVENT: Phase I Studies with Hepatitis C Compounds in Healthy Volunteers and Patients: Views from Inside
8. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
9. New head-to-head clinical studies reveal Reach Ultraclean toothbrush and floss deliver superior plaque removal compared to leading competitive products
10. New studies examine elimination of hepatitis B and C
11. By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... Open Tennis Championship tickets in NYC. In just a ... USTA Billie Jean King Tennis Center. The event was originally founded ... the 2013 event, Rafael Nadal was forced to withdrawal from the ... of the 2014 women’s tournament and will return to New York ...
(Date:8/20/2014)... in Australia examined patient and tumor characteristics for ... tumor cell growth) in an effort to increase ... , Author: Sarah Shen, M.B.B.S., ... colleagues. , Background: The tumor characteristic known ... been connected with prognosis and survival in melanoma ...
(Date:8/20/2014)... Opinion: The time to deploy Ebola vaccines is now, ... vaccines is now, according to a commentary being published ... Medicine . The authors from Yale School of ... geographic dissemination of the current Ebola outbreak represent a ... under current efforts. Several Ebola vaccines have been developed ...
(Date:8/20/2014)... of brain cells that act as a "sleep switch" ... and staying asleep, a new study suggests. In ... often results in nighttime confusion and wandering, according to ... Rush Memory and Aging Project, which includes nearly 1,000 ... followed until death, at which point their brains are ...
(Date:8/20/2014)... The Board of Directors of top international ... pleased to announce the expansion of its healthcare ... and the surrounding region. In support of this strategic ... has relocated to the firm’s office in Shanghai, China, ... design and to better support regional clients. , ...
Breaking Medicine News(10 mins):Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 2Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 4Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 5Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:News from Annals of Internal Medicine 2Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3
... most common breast cancer uses the most efficient, powerful ... that system kills it, researchers report. This method ... patients, particularly those resistant to standard therapies such as ... Human estrogen receptor-positive breast cancer cells thriving in a ...
... The second generation drug-eluting stent, everolimus-eluting stent ... in randomised controlled trials over the first ... earlier studies comparing EES with another first ... only demonstrated the non-inferiority of EES; the ...
... order to meet future demands for new pharmaceuticals, ... is dependent on the ongoing development of effective ... Because they are so versatile, organometallic molecules are ... reagents containing zinc atoms have certain advantages over ...
... , MONDAY, Aug. 29 (HealthDay News) -- Boxing ... encourage their kids to find sports that don,t focus ... Those are conclusions from the new policy statement from ... Society that recommends that pediatricians vigorously oppose children participating ...
... Meeting & OTO EXPO of the American Academy of Otolaryngology ... of ear, nose, and throat doctors in the world, will ... more than 386 scientific research sessions, 468 posters, and several ... a unique opportunity for journalists from around the world to ...
... 28 (HealthDay News) -- Although it may sound sweet ... behavior, similar to arguing or slinging insults, Canadian scientists ... Queens University in Kingston, Ontario, also revealed that differences ... live, play a role in how aggressive their shouting ...
Cached Medicine News:Health News:Research aims to starve breast cancer cells 2Health News:Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents 2Health News:New salts for chemical soups 2Health News:Pediatric Groups Want to KO Boxing for Kids 2Health News:Pediatric Groups Want to KO Boxing for Kids 3Health News:2011 AAO-HNSF poster presentations 2Health News:2011 AAO-HNSF poster presentations 3Health News:2011 AAO-HNSF poster presentations 4Health News:2011 AAO-HNSF poster presentations 5Health News:2011 AAO-HNSF poster presentations 6Health News:2011 AAO-HNSF poster presentations 7Health News:2011 AAO-HNSF poster presentations 8Health News:2011 AAO-HNSF poster presentations 9Health News:2011 AAO-HNSF poster presentations 10Health News:2011 AAO-HNSF poster presentations 11Health News:2011 AAO-HNSF poster presentations 12Health News:2011 AAO-HNSF poster presentations 13Health News:2011 AAO-HNSF poster presentations 14Health News:2011 AAO-HNSF poster presentations 15Health News:2011 AAO-HNSF poster presentations 16Health News:2011 AAO-HNSF poster presentations 17Health News:2011 AAO-HNSF poster presentations 18Health News:2011 AAO-HNSF poster presentations 19Health News:2011 AAO-HNSF poster presentations 20Health News:2011 AAO-HNSF poster presentations 21Health News:Sweet Sparrow Songs May Actually Be Shouting Matches 2
(Date:8/20/2014)... 2014 Research and Markets ... Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) ... to their offering. A new ... geography) - Size, Share, Global Trends, Company Profiles, ... Forecast, 2013 - 2020", suggests that the global ...
(Date:8/20/2014)... Research and Markets  has announced the addition ... to their offering. Global Market Report of ... globally and regionally ( Europe , ... Latin America etc.). It captures Pralmorelin market ... focuses on three primary areas; manufacture methods & technology development, ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: Global Coatings ... http://www.reportlinker.com/p01375204/Global-Coatings-for-Medical-Devices-Industry.html This report analyzes ... in US$ Million by the following Product Segments: ... Coatings. The report provides separate comprehensive analytics for ...
Breaking Medicine Technology:Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2Global Market Report of Pralmorelin 2Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21
... Pa., Aug. 22, 2011 Cephalon, Inc. (Nasdaq: ... of its 2.50 percent Convertible Senior Subordinated Notes due ... Subordinated Notes due 2015 (the "2015 Notes") in respect ... with a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., ...
... Aug. 22, 2011 Clinigene International Limited, ... Phase I-IV Clinical Research Organization, and Spaulding ... Cardiac Core Lab, and Medical Device Manufacturer, ... establishes a reliable, trustworthy, and cost-efficient global ...
Cached Medicine Technology:Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 2Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 3Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 4Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 5Spaulding Clinical Announces Strategic Partnership with Clinigene International, India for Providing Comprehensive Early Clinical Solutions to Pharmaceutical and Biotech Clients 2Spaulding Clinical Announces Strategic Partnership with Clinigene International, India for Providing Comprehensive Early Clinical Solutions to Pharmaceutical and Biotech Clients 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: